Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum

Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729–777.PubMedCrossRef 4. Liu D, Shriver Z, Qi Y, Venkataraman G, Sasisekharan R: Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 2002, 28:67–78.PubMedCrossRef 5. Pye DA, Vives RR, Hyde P, Gallagher JT: Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is

dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 2000, 10:1183–1192.PubMedCrossRef 6. Filmus J: Glypicans in growth control and cancer. Glycobiology 2001, 11:19R-23R.PubMedCrossRef 7. Folkman J: Angiogenesis-dependent check details diseases. Semin Oncol 2001, 28:536–542.PubMedCrossRef 8. Iozzo RV, San Antonio JD: Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001, 108:349–355.PubMed 9. Xiang YY,

Ladeda V, Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408–7412.PubMedCrossRef 10. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Jr: Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001, 293:1663–1666.PubMedCrossRef Apoptosis inhibitor 11. Abiatari I, Kleeff J, Li J, Felix K, Buchler MW, Friess H: Savolitinib price HSulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol 2006, 59:1052–1058.PubMedCrossRef 12. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V:

Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003, 278:23107–23117.PubMedCrossRef 13. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V: HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004, 23:1439–1447.PubMedCrossRef 14. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Celecoxib Cunningham JM, Smith DI, et al.: hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004, 126:231–248.PubMedCrossRef 15. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V: Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 2007, 26:4969–4978.PubMedCrossRef 16. Johnson AD, Wang D, Sadee W: Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther 2005, 106:19–38.PubMedCrossRef 17. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, Dai Z, Wang D, Sadee W: Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 2008, 18:781–791.

Comments are closed.